ACCESS Newswire
08 Jul 2025, 18:13 GMT+10
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:
https://www.championsoncology.com/radiopharmaceutical
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
[email protected]
518 488 9026
SOURCE: Champions Oncology, Inc.
Get a daily dose of Yorkshire Observer news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Yorkshire Observer.
More InformationNEW YORK CITY, New York: With just weeks to spare before a potential government default, U.S. lawmakers passed a sweeping tax and spending...
Washington [US], July 8 (ANI): Tech billionaire Elon Musk has escalated his feud with US President Donald Trump, announcing the formation...
Islamabad [Pakistan], July 8 (ANI): Former Pakistan Prime Minister Imran Khan and his wife Bushra Bibi on Tuesday submitted an application...
The recent military escalation against Tehran may have ended, but the efforts to remove it as an independent world power persist ...
The recent military escalation against Tehran may have ended, but the efforts to remove it as an independent world power persist ...
Beijing [China], July 8 (ANI): Yu Jing, spokesperson of Chinese Embassy in India on Tuesday said that relations with India are at a...
(Photo credit: Nathan Ray Seebeck-Imagn Images) Chelsea will try to reach a second major final in three months when they face Fluminense...
(Photo credit: Troy Taormina-Imagn Images) The Houston Dynamo extended midfielder Jack McGlynn's contract through 2028 with a club...
Ranchi (Jharkhand) [India], July 7 (ANI): As expected, legendary cricketer Mahendra Singh Dhoni celebrated his 44th birthday in a low-key...
Mumbai (Maharashtra) [India], July 7 (ANI): As MS Dhoni turned 44 on Monday, tributes poured in from all corners of the cricketing...
New Delhi [India], July 7 (ANI): India pacer Deepak Chahar extended birthday wishes to his former Chennai Super Kings teammate and...
(Photo credit: Kevin Ng-Imagn Images) Sounders goalkeeper Stefan Frei was 'back home resting' on Monday after leaving Sunday's match...